

CURRICULUM VITAE

NAME: Marcy Behar Bolster
OFFICE ADDRESS: Department of Medicine **PHONE:** (843) 792-3484
Division of Rheumatology and Immunology
Medical University of South Carolina
96 Jonathan Lucas St., Suite 912 **FAX:** (843) 792-7121
P.O. Box 250637
Charleston, SC 29425

CITIZENSHIP: U.S.A.

EDUCATION:

<u>Institution/Location</u>	<u>Years</u>	<u>Training</u>
Duke University, Durham, North Carolina	1980-84	B.A., Chemistry
Duke University School of Medicine, Durham, North Carolina	1984-88	M.D.
Internship: Intern, Internal Medicine, Eastern Virginia Graduate School of Medicine, Norfolk, Virginia	7/88-6/89	
Residency: Resident, Internal Medicine, Eastern Virginia Graduate School of Medicine, Norfolk, Virginia	7/89-6/91	
Fellowship: Fellow, Rheumatology Medical University of South Carolina Charleston, South Carolina	7/91-6/93	

SPECIALTY CERTIFICATION:

1991	Internal Medicine
1994	Rheumatology
2000	Certification by International Society of Clinical Densitometry
2001	Internal Medicine (recertification)
2004	Rheumatology (recertification)
2004	International Society of Clinical Densitometry (recertification)

LICENSURE:

1989-1991	Virginia
1991-present	South Carolina (SCLN 15427)

FACULTY APPOINTMENTS:

<u>Years</u>	<u>Rank</u>	<u>Institution</u>	<u>Dept.</u>
7/93-7/94	Instructor	MUSC, Charleston	Medicine
7/94-6/00	Assistant Professor	MUSC, Charleston	Medicine
7/00	Associate Professor	MUSC, Charleston	Medicine

2002	Associate Professor	MUSC, Charleston	Graduate Studies
1/04	Associate Professor with Tenure	MUSC, Charleston	Medicine
7/08 – present	Professor of Medicine	MUSC, Charleston	Medicine

ADMINISTRATIVE APPOINTMENTS:

8/94-6/96	Chief, Rheumatology	Ralph H. Johnson VA Charleston	Medicine
7/99-present	Director, Rheumatology Fellowship Program	MUSC, Charleston	Medicine
2/08-present	Medical Director Musculoskeletal Service Line	MUSC	Medicine

HOSPITAL PRIVILEGES:

1993-present	Medical University Hospital (active)
1993-present	Ralph H. Johnson VA Medical Center (active)

MEMBERSHIP IN PROFESSIONAL/SCIENTIFIC SOCIETIES:

1989-2005	American College of Physicians
1991-present	S.C. Rheumatism Association
1992-present	American College of Rheumatology
1994-present	Charleston County Medical Society
1994-present	South Carolina Medical Association
1996-present	Scleroderma Clinical Trials Consortium
1998-2001	S.C. Rheumatism Association Meeting Planning Committee
1999-present	Arthritis Foundation
2004-present	International Society of Clinical Densitometry
2004-2005	Pulmonary Hypertension Clinicians and Researchers
2005-present	American College of Physicians (fellow)

GRANT SUPPORT:

Previous:

1993-1994	\$89,731; Showa Denko K.K. “Role of Mg Deficiency in EMS”, Co-I
1996-1997	\$25,000; Environmental Hazards Assessment Program (EHAP), DOE “TCE Exposure and Scleroderma-Development of a SSc Patient Database”, PI subproject
2000-2002	\$3,500; Ilex Oncology; “Oxypurinol in Gout Patients Unable to Tolerate Allopurinol,” PI
7/01-6/03	\$94,500; Knoll/Abbott Clinical Fellowship Chair-An award for support of a clinical fellowship training position
7/02-6/03	\$25,000; Amgen Research Fellowship Award for “Detection of osteoporosis in African-American patients with sarcoidosis”, Research fellowship for

rheumatology fellow to perform a pilot study to determine bone mineral density in African-Americans with sarcoidosis and to determine if sarcoidosis is an independent risk factor for osteoporosis, after factoring out other recognized risk factors. Dr. Bolster serves as mentor.

- 7/03 – 6/04 \$40,000; CHORD Fellowship (Centocor)
“Cardiovascular Outcomes in Systemic Lupus Erythematosus: Case Control Study”, (Dr. Fred Wolfe and Dr. Bolster will be mentors)
- \$25,000; Amgen Fellowship Award, “Cardiovascular disease risk in young rheumatoid arthritis patients,” (Dr. Bolster is the mentor)
- 7/99-6/05 \$608,152; NIH RO1 HL60750-4; “Scleroderma Lung Study - Cyclophosphamide vs. Placebo in Scleroderma Pulmonary Alveolitis”, Co-I
- 9/99-03/05 NIH N01 AR9224 (subcontract), Multicenter trial of oral Type I bovine collagen in scleroderma, CO-PI (Postlewaithe-Lead PI)
- 10/00-10/05 \$16,120; Abbott (Knoll) Pharmaceuticals; “Study of New Onset Rheumatoid Arthritis (SONORA Registry)”, PI
- 7/03-6/05 \$105,000; Thomas Memorial Hospital, Charleston, West Virginia
Clinical Fellowship-Award to support a clinical fellowship training position.
- 7/04-6/05 \$25,000: Amgen Fellowship Award, “Osteoporosis in African-American patients with systemic sclerosis,” (Dr. Bolster is the mentor)
- 7/03 – 6/05 \$40,000: Centocor CHORD Fellowship Award (Dr. Bolster is mentor)
Centocor and National Data Bank for Rheumatic Diseases
- 4/03-3/08 \$863,116 total DC; “MCRC for Rheumatic Diseases in African-Americans”,
NIAMS P60 AR49459-01
\$140,053; Patient Resource Core
Multidisciplinary Clinical Research Center grant consisting of 3 cores and 3 clinical research projects focusing on the effects of scleroderma and systemic lupus erythematosus, particularly in African-Americans.
- 10/05-3/09 \$20,000; Genentech Protocol number U3374. Rituximab immune response in Rheumatoid Arthritis patients taking Methotrexate. (SIERRA)

Current:

- 12/05-10/10 \$124,188; Genentech Protocol number WA17045/U2973g, "A Randomized, Placebo Controlled, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Rituximab (MabThera/Rituxan) in

Combination with Methotrexate, Compared to Methotrexate Monotherapy, in Patients with Active Rheumatoid Arthritis."

- 7/05-6/10 \$164,799;NIAMS Protocol number T32 AR050958-02. Training Grant in Inflammatory and Fibrosing Diseases. Grant to focus on defining societal, environmental and genetic factors that impact morbidity and mortality in African Americans with rheumatic diseases, specifically lupus and scleroderma.
- 2/06-6/09 \$13,000;PHAROS study, PI. Pulmonary Hypertension Assessment Registry of Scleroderma.
- 10/06-8/11 \$125,000;Genentech Protocol number ACT3985g, PI. Ocrelizumab vs. placebo in Rheumatoid Arthritis patients taking Methotrexate.
- 4/07-10/12 \$200,000;Genentech Protocol number ACT3984g, PI. Ocrelizumab and Methotrexate in Rheumatoid Arthritis in Methotrexate naive patients.
- 5/07-8/12 \$130,000;Genentech protocol number ACT3986g, PI. Ocrelizumab vs. placebo in Rheumatoid Arthritis patients failing antin-TNF a therapy.
- 4/1/08-3/31/09 \$53, 291 Feinstein Institute for Medical Research-Autoimmunity Centers of Excellence. NIH U19AI056362, PI. A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid Arthritis

AWARDS, HONORS, MEMBERSHIP IN HONORARY SOCIETIES:

- 1980-1984 North Carolina Merit Scholarship
- 1981 Phi Eta Sigma Freshman Honor Society
- 1984 Magna Cum Laude with Honors in Chemistry
Phi Lambda Upsilon Chemistry Honor Society
- 1986-1987 American Heart Association Research Scholarship, Duke University, Durham, North Carolina
- 1988 Alpha Omega Alpha Honor Society
Merck Manual Award
- 1990 The Sir William Osler Award - Intern Teaching Award
- 1991 Senior Resident Research Award
- 1998 Applause Award - Patient Recognition Award
- 1998 Arthritis Foundation Award - Volunteer Service Recognition Award
- 2004-2008 Best Doctors in America
- 2006 American College of Rheumatology REF Medical Student Clinical Preceptorship Award
- 2007 American College of Rheumatology REF Medical Student Clinical Preceptorship Award

ACADEMIC COMMITTEE ACTIVITIES:

- 1994-1996 Pharmacy and Therapeutics, Ralph H. Johnson VA Medical Center
- 1998-2006 Pharmacy and Therapeutics, Medical University of South Carolina

- 1998-present Intern Selection Committee, Department of Medicine, Medical University of South Carolina
- 1999-present Graduate Medical Education Committee (Rheumatology Fellowship Director)
- 2000 Bone and Joint Center Transition Team
- 2000-present Fellowship Training Outcomes Subcommittee (American College of Rheumatology)
- 2001-2007 Abbott Scholar Award Committee Member
- 2004-2006 American College of Physicians MKSAP14- Rheumatology Committee Member
- 2005-present Musculoskeletal Radiology Fellowship Interview Committee
- 2006-present Division Educational Representative, Department of Medicine, MUSC
- 2006-present College of Medicine Curriculum -Course evaluation subcommittee
- 2006 Abbott Scholar Retreat - Meeting Co-Chair
- 2006-present Co-chair, Rheumatology Fellows In-training Exam Committee
- 2006-present Promotion and Tenure Committee, DoM, MUSC
- 2006-2008 American College of Physicians, Scientific Meeting Planning Committee
- 2006-2009 American College of Rheumatology, Scientific Meeting Planning Committee for 2007
- 2006-2007 American College of Physicians MKSAP14 Update
- 2007-present Geriatric Fracture Programs Charter Committee Member, MUSC
- 2007 Member of Abstract Committee for Scleroderma and Fibrosing Diseases: Clinical Aspects and Therapeutics Section, American College of Rheumatology Annual Conference.
- 2007 Training Resources Committee for the American College of Rheumatology.
- 2007 American College of Physicians MKSAP15 – Rheumatology Book Editor.
- 1/08-present Resident Education Sub-Committee, Chair. Committee on Training and Workforce, ACR.
- 2008 American College of Rheumatology Abstract Selection Committee: Systemic sclerosis, fibrosing syndromes and Raynaud’s: clinical aspects and therapeutics
- 8/08-present Vertebral Fracture Program, Chair – Charter Committee Member, MUSC
- 12/08-present Total Joint Arthroplasty Committee, MUSC

Education – Teaching:

- 1997-present Director of Internal Medicine Housestaff Education on Rheumatology Service
- 1993-present Physical Diagnosis: First semester: small group education of physical exam techniques
Second semester: small group education with patient interview and physical examination.
- 1993-present Clinical education
Mentoring of medical students, internal medicine residents and rheumatology fellows in rheumatology clinics at MUH.
Attending physician on the rheumatology consult teaching service

	and VA inpatient medical service.
2000-2006	Graduate Studies Education Thesis Committee member for Dr. Kristin Highland – Masters in Clinical Research (2000-2006) Thesis Committee member for Dr. Diane Kamen – Masters in Clinical Research (2002-2004)
10/03/2003	CME course Director, “Early Identification and Management of Inflammatory Arthritis for the Primary Care Physician”
7/2004, 7/2005 7/2006, 7/2007	Carolina Fellows’ Symposium, Winston – Salem, North Carolina
11/13/04	CME Course Director – “Identification and Management of Early Polyarthritis”
11/04/05	CME Course Co-Director – “Rheumatology for the Primary Care Physician”
2006 - Present	Data and Safety Monitoring Board member for Dr. Diane Kamen’s study – “ Vitamin D Therapy in Patients with Systemic Lupus Erythematosus”
10/14/06-10/15/06	CME Course Director – “Bone and Joint Disorders Facing Primary Care Providers”
1/19/07 – 1/21/07	Carolina Fellows’ Symposium. Charleston, South Carolina

MAJOR CLINICAL INTERESTS:

General rheumatology
Scleroderma lung disease
Rheumatoid Arthritis
Osteoporosis
MUSC Sarcoidosis Consortium member

MAJOR RESEARCH INTERESTS:

Computerized longitudinal Connective Tissue database - development and perpetuation
Scleroderma Lung Disease
Rheumatoid Arthritis
Osteoporosis

LECTURES AND PRESENTATIONS:

Invited Lectures:

- *October 2000 “An Update in the Management of Scleroderma” Southeastern Consortium of Dermatology, Charleston, South Carolina
- *January 2001 “Churg Strauss Vasculitis” Internal Medicine Grand Rounds, MUSC, Charleston, South Carolina
- July 2001 “Management of Osteoporosis” Ralph H. Johnson, VA Medical Center, Charleston, South Carolina
- *August 2001 “Extra-Articular Manifestations of Rheumatoid Arthritis” Internal Medicine Grand Rounds, Greenville Hospital Systems, Greenville, South Carolina
- *October 2002 “Mentoring in Academic Medicine” American College of Rheumatology, 65th Annual Scientific Meeting, New Orleans, LA

- November 2002 Peer Discussion Group “Difficult to Manage Osteoarthritis” Merck Lectureship, Charleston, South Carolina
- November 2002 “Mentoring in Academic Medicine” Department of Medicine Research Grand Rounds, MUSC, Charleston, South Carolina
- *November 2002 “Rheumatoid Arthritis and Systemic Lupus Erythematosus” Women’s Health Conference, Charleston, South Carolina
- January 2003 “Humira: More Normal Living,” Satellite presentation, Moderator, Abbott Pharmaceuticals, Charleston, South Carolina
- *February 2003 “Polymyalgia Rheumatica and Giant Cell Arteritis” Neurology Grand Rounds, MUSC, Charleston, South Carolina
- *February 2003 “An Update in Osteoporosis and the Use of Teriparatide” Rheumatology Grand Rounds, MUSC, Charleston, South Carolina
- *October 2003 “The Role of Biologic Agents in the Management of Inflammatory Arthritis” Primary Care CME Conference, Charleston, South Carolina
- May 2004 “Update on the Use of Biologic Agents in RA” Abbott Lectureship, Charleston, South Carolina
- July 2004 “Recognition and Management of Osteoporosis” Proctor and Gamble Lectureship, Charleston, South Carolina
- October 2004 “Mentoring in Rheumatology” Women in Rheumatology Conference, New York, New York
- *November 2004 “The Roles of Biologic Agents in the Treatment of RA,” CME program “Identification and Management of Early Polyarthritis”
- March 2005 “Osteoporosis: The Impact, Detection, and Management” Department of Medicine, Resident’s Noon Conference. Medical University of South Carolina, Charleston, SC
- August 2005 “Update on B Cell Biology: Role in RA” Genentech Lectureship. Augusta, Georgia.
- *November 2005 “Update in Osteoporosis”, Rheumatology for the Primary Care Physician, CME Conference, Hilton Head, SC
- *November 2005 “The Use of Biologic Agents in treating RA, Psoriatic Arthritis and Ankylosing Spondylitis”, Rheumatology for the Primary Care Physician, CME Conference, Hilton Head, SC
- *January 2006 “Late-Breaking News in Osteoporosis”, Medicine Grand Rounds, MUSC, Charleston, SC
- *January 2006 “Update on Therapies in Osteoporosis: Calcium and Vitamin D”, Dept. of Nursing, MUSC, Charleston, SC
- *July 2006 “Osteoporosis for the Orthopedic Surgeon”, Department of Orthopedics, MUSC.
- *October 2006 “Update in Osteoporosis”, Bone and Joint Disorders Facing Primary Care Providers, CME Conference, Charleston, SC
- * March 2007 “The Use of Immunosuppressive Medications in Non-Cancer Patients,” Med U Way Conference, Pharmacy Services, MUSC
- October 2008 “Osteoporosis: What is New in the Toolbox?”, Rheumatology Grand Rounds, MUSC
- November 2008 Rheumatology Division Rounds, Washington University, St. Louis, MO
“When it is Not Systemic Sclerosis: Other Fibrosing Skin Conditions”
November 20, 2008

April 2008 “Osteoporosis for the Neurologist”, Neurology Grand Rounds, MUSC, April 23, 2009.

* indicates CME presentations

Submitted Presentations:

1. Bolster MB, Allen NB, Heyes MP, Silver RM. Enhancement of the kynurenine pathway of L-tryptophan metabolism in eosinophilic fasciitis. ACR 57th Annual Scientific Meeting, San Antonio, TX; November 7-11, 1993.
2. Bolster MB, Ludwicka A, Strange C, LeRoy EC. Silver RM. Cytokines in bronchoalveolar lavage (BAL) fluid of patients with systemic sclerosis (SSc). ACR 58th Annual Scientific Meeting, Minneapolis, MN; October 23-27, 1994
3. +Mitchell HC, Bolster MB, Coppage L, Schabel SI, Sutherland SE, Strange C, Silver RM. High-resolution computed tomography (HRCT) as a means of assessing interstitial lung disease in patients with systemic sclerosis. ACR 60th National Scientific Meeting, Orlando, FL; October 18-22, 1996.
4. +Senseney J, Ludwicka A, Bolster, MB, Silver RM. The effects of daily oral cyclophosphamide on BAL findings in active scleroderma lung disease. ACR 62nd National Meeting; San Diego, CA; November 8-12, 1998.
5. +Taylor M, Bolster MB, McFadden J, Silver RM. Ulnar artery involvement in systemic sclerosis (scleroderma). ACR 62nd National Meeting; San Diego, CA; November 8-12, 1998.
6. +Taylor MH, Usher BW, Bolster MB, Silver RM. Detection of primary diastolic dysfunction of the right ventricle in systemic sclerosis. ACR 63rd Annual Scientific Meeting, Boston, MA; November 13-17, 1999.
7. +Brown AN, Michel YG, Mitchell HM, Bolster MB. An Epidemiological Study of Scleroderma Patients in South Carolina. *Arthritis and Rheum* 2000; 44:9 (5).
8. Clements, PJ, Tashkin, D, Roth M, Silver, RM, Bolster, MB. Concordance of HRCT and BAL at Entry into the Scleroderma-Lung Study (SLS). ACR 65^h Annual Scientific Meeting, New Orleans, LA: October 25-29, 2002.
9. Strange, C., Silver, R., Bolster, M., Roth, M., Goldin, J., Elashoff, R., Clements, P.J., Tashkin, D., and the SLS Investigators. Concordance of BAL and HRCT in the Scleroderma Lung Study (SLS). *Amer Thoracic Society Meeting* 2003, Seattle, WA.
10. +Fahey, S., Bolster, Judson, M. Bone Mineral Density in African-Americans with Sarcoidosis. 2003 Amgen Fellowship Symposium, Rancho Mirage, California.
11. Nietert, P., Mitchell, H., +Curran, M., Bolster, M., Silver, R. Racial disparities in quality of life among patients with systemic sclerosis. 2003 Amer College Rheumatol Annual Mtg, Orlando, FL, October, 2003.
12. Mitchell, H., Nietert, P., Bolster, M., Silver, R. Racial variation in clinical, serologic and immunologic manifestations of systemic sclerosis (SSc). 2003 Amer College Rheumatol Annual Mtg, Orlando, FL, October, 2003.
13. Nietert PJ, Shaftman SR, Tilley BC, Bolster MB, Silver RM. Patterns of Emergency Room Visits in a Multi-Ethnic Population of Patients with Systemic Sclerosis. *Arthritis Rheum* 50:S84-85, 2004.
14. Nietert PJ, Silver RM, Bolster MB, Mitchell HC, Tilley BC, Shaftman SR. The Influence of Renal Disease and Race on In-Hospital Mortality Among Patients with Systemic Sclerosis. *Arthritis Rheum* 50:S421, 2004.
15. Nietert PJ, Mitchell HC, Bolster MB, Curran MY, Silver RM. How Do Functional Status and Gastrointestinal Dysfunction Influence Depression Among Patients with Systemic

- Sclerosis? *Arthritis Rheum* 50:S464, 2004.
16. Strange C, Bolster M, Roth M, Golden J, Clements P, Elashoff R, Tashkin DP, Smith E, Silver RM, and the Scleroderma Research Group. Bronchoalveolar Lavage Cellularity Does not Predict Cyclophosphamide Response In Scleroderma Interstitial Lung Disease. 2005 American Thoracic Society.
 17. +Beall A, Nietert PJ, Shaftman SR, et al. Pulmonary Hypertension and Mortality in a Cohort of Patients with Systemic Sclerosis. Professor E. Carwile LeRoy Memorial International Workshop on Scleroderma, May, 2007. Tokyo, Japan.
 18. Nietert PJ, Bolster MB, Silver RM. Development and Validation of a Systemic Sclerosis In-Hospital Mortality Risk Adjustment Index. Professor E. Carwile LeRoy Memorial International Workshop on Scleroderma, May, 2007. Tokyo, Japan.
 19. +Hant FN, Hermayer K, Whyte MP, Bolster MB. Possible Hypophosphatasia in a man with hypophosphatasemia, Spinal Ankylosis, and recurrent fractures. ASBMR 29th Annual Meeting, Honolulu, HI, September, 2007.
 20. Kim H, Goldin J, Lynch D, Strollo D, Strange C, Silver R, Bolster M, Vasu F, Ochs R, Gjertson D, Elashoff R, Roth M, Furst D, Clements P, Tashkin D, Los Angeles, CA. [Poster Board #A11] Bronchoalveolar Lavage Correlated with Quantitative Lung Fibrosis and Ground Glass, [Publication Page: A882]. ATS abstract presented May, 2008.
 21. +Daniel R, Bourne R, Simpson A, O'Rourke K, Bolster M. Predictors of Response to anti-TNF- α Therapies in Two University –Based Rheumatology Populations with Rheumatoid Arthritis. *J Investig Med* 2009; 57(1): 368 (abstract #242). January 2009.

+ denotes abstracts by Dr. Bolster's trainees

COMMUNITY:

- | | |
|-----------------|---|
| 1998 | Co-chairperson, Arthritis Foundation Wine Tasting and Silent Auction Fundraiser |
| 1998 | Chairperson, CharlesTowne Montessori School, Live Auction Fundraiser |
| 1998-2000 | Board of Directors, CharlesTowne Montessori School |
| 2000, 2004 | School-To-Careers Shadowing Program for high school students |
| September, 2006 | Community Education in Osteoporosis, Bone & Joint Center |
| November, 2006 | Community Education in Osteoporosis, Bone & Joint Center |
| May, 2007 | Community Education in Osteoporosis, Wild Dunes, SC |
| August, 2007 | Community Education in Osteoporosis, ICYou.com (web-based education) |
| 2007 – 2009 | B'nai Brith Youth Organization Parent Board |

PROFESSIONAL DEVELOPMENT:

- | | |
|--------|--|
| 2/8/08 | ACR Leadership Development Course, Washington DC |
|--------|--|

PUBLICATIONS:

Peer Reviewed Journal Articles

1. Feldman MD, Behar M. A case of massive diphenhydramine abuse and withdrawal from use of the drug. *JAMA* 1986;255:3119-3120.
2. Bolster MB, Maricq HR, Leff RL. Office evaluation and treatment of Raynaud's phenomenon. *Cleveland Clinic Journal of Medicine* 1995;62:51-61.

3. Middaugh LD, Nussbaum R, Ludwicka A, Bolster MB, Silver RM. Cognitive deficits in a murine model of the eosinophilia-myalgia syndrome: A preliminary report. *Neurotoxicology and Teratology* 1996;18:595-601.
4. Suzuki S, Tourkina E, Ludwicka A, Hampton M, Bolster M, Maize J, Silver R. A contaminant of L-tryptophan enhances expression of dermal collagen in a murine model of the eosinophilia myalgia syndrome. *Proc Assoc Am Phys* 1996;108:315-322.
5. Bolster MB, Silver RM. Therapy of scleroderma lung disease. *Clin Pulm Med* 1996;3:314-322.
6. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. *Arthritis Rheum* 1997;40:743-751.
7. Bolster MB, Silver RM. Lung disease in systemic sclerosis (scleroderma). *Semin Respir Crit Care Med* 1999;20:109-120.
8. Bolster MB, LeRoy EC. Scleroderma: How to recognize and treat. *Women's Health Primary Care* 1999;2:183-194.
9. Strange C, Bolster M, Mazur J, +Taylor M, Gossage JR, Silver R. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. *Chest*, 118:1077-1082, 2000.
10. Huabei, J, Key L, Bolster, MB. In vivo detection of osteoarthritis with diffuse optical tomography. Special Issue: Lasers in Medicine and Biology. *Optics Express*, 8 (7):447-451 March 2001
11. +Niemer GW., Bolster MB., Buxbaum L., Judson MA. Carpal tunnel syndrome in sarcoidosis. *Sarcoidosis Vasculitis & Diffuse Lung Diseases*. 18(3):296-300, 2001.
12. +Taylor MH, Bolster MB, McFadden J, Silver RM . Ulnar artery involvement in systemic sclerosis (scleroderma). *J Rheumatology* 29:102-106, 2002.
13. +Brown AN, Bolster MB. Scleroderma renal crisis in pregnancy associated with massive proteinuria. *Clinical and Experimental Rheumatology* 2003; 21: 114-16.
14. +Taylor JG, Bolster MB. Bronchiolitis obliterations with organizing pneumonia associated with scleroderma and scleroderma spectrum diseases. *J of Clin Rheum*, 9(4):239-245, 2003.
15. +Douglas GC, +Bird KS, Flume PA, Silver RM, Bolster MB. Wegener's Granulomatosis in patients with Rheumatoid Arthritis. *Journal of Rheumatology*. 30: 2064-9, 2003.
16. Strange C, Silver R, Bolster M, Roth M, Goldin J, Elashoff R, Clements PJ, Tashkin D, the SLS investigators. Concordance of BAL and HRCT in the Scleroderma Lung Study. *AM Rev Respir Crit Care Med* 2003; 167:A474
17. Nietert, P., Mitchell, H., Bolster, M.B., Curran, M.Y., Tilley, B.C., and Silver, R.M. Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. *J Rheumatol* 32:51-7, 2005.
18. Nietert PJ, Mitchell HC, Bolster MB, Shaftman SR, Tilley BC, Silver RM. Racial variation in clinical and immunological manifestations of systemic sclerosis. *J Rheumatol* 33:263-8; 2006.
19. Tashkin DP, Elashoff R, Clements PJ, Bolster MB, et al., for the Scleroderma Lung Study Group. Cyclophosphamide versus Placebo in Scleroderma Lung Disease. *NEJM* 354:2655-2666; 2006.
20. Clements, P.J., Elashoff, R., Roth, M.D., et al., for the Scleroderma Lung Study Group. Scleroderma Lung Study (SLS): A comparison of patients with limited systemic sclerosis (SSc) versus diffuse SSc at entry. Submitted.

21. +Beall A, , Nietert PJ, Taylor MH, Mitchell HC, Shaftman SR, Silver RM, Smith EA, and Bolster MB. Ethnic disparities in patients with Pulmonary Arterial Hypertension associated with Systemic Sclerosis. *J Rheumatol* 34:1277-82; 2007.
22. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver RM, Strange C, Bolster MB, et al. Impact of Oral Cyclophosphamide on Health-Related Quality of Life in Patients with Active Scleroderma Lung Disease. Results from the Scleroderma Lung Study. *Arthritis Rheum.* 56:1676-84, 2007.
23. Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster MB, et al. Scleroderma Lung Study (SLS): Differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. *Ann Rheum Dis.* doi: 10.1136/ard.2007.069518. 7 May 2007.
24. Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar Lavage and Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease. *Am J Resp Crit Care Med*, 2008 Jan 1;177(1):91-8. Epub 2007 Sep 27.
25. PMID: 17901414 Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, strange C, Bolster MB, et al for the Scleroderma Lung Study (SLS) research Group. Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 years in Scleroderma Lung Study. *Am J Resp Crit Care Med*, Vol. 76. pp1026-1034, 2007.
26. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR and Furst DE for the Eposs-Omeract Group. Defining Appropriate Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: A Delphi Consensus Study with Cluster Analysis. *Arthritis Rheum* 59: 867-875, 2008.

Non-peer Reviewed Articles:

1. Bolster MB, Silver RM. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. *Current Opinion in Rheumatology* 1994;6:642-649.
2. Bolster MB and Silver RM. Assessment and management of scleroderma lung disease. *Curr Opin Rheumatol* 11:508-513, 1999

Chapters:

1. Bolster MB, Silver RM. Lung disease in systemic sclerosis. In: Lung Disease in Rheumatic Disorders. Kelly C, ed. London:Bailliere Tindall, 1993:79-97.
2. +Mitchell H, Bolster MB, LeRoy EC. Scleroderma and related conditions. In: Med Clin NA 1997;81:129-149.
3. Silver RM, Bolster MB. Systemic sclerosis (scleroderma). In: Samter's Immunological Diseases, Sixth Edition; Austen, Frank, Atkinson & Cantor, eds., Lippincott Williams & Wilkins, Baltimore, pp. 504-519, 2001.
4. Silver, R.M. and Bolster, M.B. Variant forms of scleroderma. In: Arthritis and Allied Conditions, 14th edition, W.J. Koopman, ed., Williams & Wilkins, Baltimore, pp. 1625-1642, 2001.
5. Bolster, M.B. and Silver, R.M. Other fibrosing disorders. In: Systemic Sclerosis, 2nd edition, Clements PJ and Furst DE, eds. Lippincott, Williams & Wilkins, Baltimore, pp. 121-127, 2004.
6. Silver, RM., Medsger, TA., Bolster, MB. Systemic Sclerosis and Scleroderma Variants: Clinical Aspects, W.J. Koopman, ed. In: Arthritis and Allied Conditions, 15th edition, W.J. Koopman, ed., Lippincott, Williams & Wilkins, Baltimore, pp. 1633-1680, 2005.
7. Bolster MB, Silver RM. Clinical Features of Systemic Sclerosis. In: Rheumatology, 4th edition, Hochberg, Silman, Smolen, Weinblatt, and Weisman, eds. Elsevier Ltd., Edinburgh, pp. 1375-

- 1385, 2007.
8. Bolster MB and Monu JUV. Rheumatoid Arthritis. In: Imaging of the Musculoskeletal System, Vol II. Pope, Bloem, Beltran, Morrison, & Wilson, eds. Saunders/Elsevier, Philadelphia, pp. 1100-1112, 2008.

Peer Reviewed Electronic Publications:

1. Silver, RM., Bolster, MB. PIER-Computerized module of Scleroderma for American College of Physicians (updated Quarterly). 2002

+denotes publications by Dr. Bolster's trainees